keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
LCKLSL, an N-terminal hexapeptide, acts as a competitive inhibitor of annexin A2 (AnxA2), effectively preventing the binding of tissue plasminogen activator (tPA) to AnxA2 while also inhibiting the generation of plasmin. In addition, LCKLSL exhibits anti-angiogenic properties.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | Inquiry | $ 1,088.00 |
Description | LCKLSL, an N-terminal hexapeptide, acts as a competitive inhibitor of annexin A2 (AnxA2), effectively preventing the binding of tissue plasminogen activator (tPA) to AnxA2 while also inhibiting the generation of plasmin. In addition, LCKLSL exhibits anti-angiogenic properties. |
In vitro | In human retinal microvascular endothelial cells (RMVECs), administering LCKLSL at doses ranging from 0 to 2 mg reduces plasmin production and diminishes the activity of tissue plasminogen activator (tPA) stimulated by vascular endothelial growth factor (VEGF) under conditions of low oxygen (hypoxia)[1]. |
In vivo | Utilizing LCKLSL in two in vivo models (in chicken chorioallantoic membrane and murine Matrigel plug assays) for studying angiogenesis has shown to inhibit angiogenic responses. Administering the LCKLSL peptide considerably reduces vascular length. Furthermore, at a concentration of 5 μg/mL, it markedly diminishes vascular branch, junction, and end-point counts[1]. |
Molecular Weight | 675.89 |
Formula | C30H57N7O8S |
CAS No. | 533902-29-3 |
keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
LCKLSL 533902-29-3 inhibitor inhibit